Masako Toyosaki

Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients

Makoto Onizuka, Nanae Kunii, Masako Toyosaki et al. · Bone Marrow Transplantation · 2010 · 47 citations

Medicine, Pharmacokinetics, Pharmacology +17

Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation

Makoto Onizuka, Minoru Kojima, Keiko Matsui et al. · International Journal of Hematology · 2017 · 38 citations

Medicine, Hematology, Oncology +17

An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease

Noriko Doki, Masako Toyosaki, Souichi Shiratori et al. · Transplantation and Cellular Therapy · 2021 · 33 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

An open‐label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid‐dependent/steroid‐resistant chronic GVHD

Yoshihiro Inamoto, Koji Kato, Toshiro Kawakita et al. · American Journal of Hematology · 2024 · 26 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +9

Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy

Jun Amaki, Makoto Onizuka, Ken Ohmachi et al. · International Journal of Hematology · 2015 · 21 citations

Medicine, Genetics, Molecular Genetics +15